newsfilter
← Latest News
PR Newswire·

UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis

Phase 3 RAISE and MycarinG studies in generalized myasthenia gravis (gMG) show zilucoplan and rozanolixizumab improve gMG-specific outcomes with consistent statistical significance and clinical relevance Regulatory submissions for zilucoplan and rozano